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We thank Zeuzem et al for their response to our recently published findings (1, 2 In summary, the available, modest data suggest that NS5A polymorphisms, which may impact treatment response are common in HCV strains from certain African genotypes.
The impact of these polymorphisms appears to be minimal in patients receiving SOF/VELbased regimens but there are concerns about the efficacy of LDV in these isolates. Further studies examining the effectiveness of current therapies in larger numbers of patients will be required to identify the optimum regimen for these potentially resistant subtypes.
